NCT04811443 - DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

June 12, 2022

Study Completion Date

June 12, 2022

Conditions

Patients With Solid Tumours Who Receive Myelosupressive Therapy

Interventions

DRUG

Empegfilgrastim

Extimia®

Trial Locations (3)

RECRUITING

Regional Clinical Oncology Hospital, Yaroslavl

RECRUITING

"State Health Institution Voronezh Region Clinical Oncology Dispansary", Voronezh

RECRUITING

St. Josaphat Belgorod Regional Clinical Hospital, Belgorod